Octagon Capital Advisors
Latest statistics and disclosures from Octagon Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APLS, VRNA, GPCR, INSM, DNTH, and represent 45.12% of Octagon Capital Advisors's stock portfolio.
- Added to shares of these 10 stocks: NUVB (+$27M), COGT (+$14M), CRBP (+$13M), PHVS (+$12M), VRDN (+$5.7M), MNMD, Cybin, AVBP, UNCY, BDTX.
- Started 7 new stock positions in NGNE, Cybin, NUVB.WS, COGT, UNCY, PHVS, BDTX.
- Reduced shares in these 10 stocks: DYN (-$33M), INSM (-$16M), TERN (-$9.3M), PRAX (-$7.5M), ANTX (-$6.9M), AKRO (-$6.6M), JSPR (-$6.5M), APLS (-$6.5M), CNTA (-$5.3M), CYBN (-$5.0M).
- Sold out of its positions in ACET, AKRO, ANTX, CYBN, ELEV, FATE, JSPR, PSTX, SLN, TERN.
- Octagon Capital Advisors was a net seller of stock by $-26M.
- Octagon Capital Advisors has $643M in assets under management (AUM), dropping by 1.04%.
- Central Index Key (CIK): 0001839435
Tip: Access up to 7 years of quarterly data
Positions held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 41 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals (APLS) | 13.5 | $87M | -6% | 3.0M | 28.84 |
|
| Verona Pharma Sponsored Ads (VRNA) | 8.2 | $53M | -3% | 1.8M | 28.77 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 8.2 | $53M | +5% | 1.2M | 43.89 |
|
| Insmed Com Par $.01 Call Option (INSM) | 7.8 | $50M | -23% | 687k | 73.00 |
|
| Dianthus Therapeutics (DNTH) | 7.4 | $48M | 1.7M | 27.38 |
|
|
| Arrivent Biopharma (AVBP) | 7.2 | $46M | +9% | 2.0M | 23.50 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 5.0 | $32M | -14% | 2.0M | 15.99 |
|
| Nuvation Bio Com Cl A (NUVB) | 4.3 | $28M | +2720% | 12M | 2.29 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 3.6 | $23M | +128% | 1.1M | 20.63 |
|
| Ocular Therapeutix (OCUL) | 3.3 | $21M | 2.4M | 8.70 |
|
|
| Miragen Therapeutics (VRDN) | 3.1 | $20M | +40% | 870k | 22.75 |
|
| Perspective Therapeutics Com New (CATX) | 3.0 | $19M | -10% | 1.4M | 13.35 |
|
| Mind Medicine Mindmed Com New (MNMD) | 2.7 | $17M | +40% | 3.0M | 5.69 |
|
| Cogent Biosciences (COGT) | 2.2 | $14M | NEW | 1.3M | 10.80 |
|
| Bridgebio Pharma (BBIO) | 2.2 | $14M | -20% | 552k | 25.46 |
|
| Pharvaris N V (PHVS) | 1.8 | $12M | NEW | 621k | 18.52 |
|
| Dyne Therapeutics (DYN) | 1.5 | $9.4M | -77% | 263k | 35.92 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 1.4 | $9.2M | 4.6M | 2.01 |
|
|
| Gossamer Bio (GOSS) | 1.4 | $9.1M | 9.2M | 0.99 |
|
|
| Allovir (ALVR) | 1.4 | $9.1M | +14% | 11M | 0.81 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 1.4 | $8.7M | 1.1M | 7.99 |
|
|
| Praxis Precision Medicines I Com New (PRAX) | 1.2 | $7.5M | -50% | 130k | 57.54 |
|
| Mineralys Therapeutics (MLYS) | 1.1 | $7.3M | 600k | 12.11 |
|
|
| Regulus Therapeutics (RGLS) | 1.0 | $6.7M | 4.3M | 1.57 |
|
|
| Ventyx Biosciences (VTYX) | 0.8 | $5.2M | 2.4M | 2.18 |
|
|
| Tenaya Therapeutics (TNYA) | 0.8 | $5.0M | 2.6M | 1.93 |
|
|
| Cybin | 0.7 | $4.4M | NEW | 490k | 8.89 |
|
| Reneo Pharmaceuticals (RPHM) | 0.6 | $3.8M | 2.3M | 1.70 |
|
|
| Unicycive Therapeutics (UNCY) | 0.5 | $3.5M | NEW | 8.6M | 0.41 |
|
| Pepgen (PEPG) | 0.5 | $3.2M | 376k | 8.55 |
|
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 0.4 | $2.6M | 250k | 10.45 |
|
|
| Black Diamond Therapeutics (BDTX) | 0.4 | $2.6M | NEW | 594k | 4.35 |
|
| Annexon (ANNX) | 0.4 | $2.4M | 400k | 5.92 |
|
|
| Mersana Therapeutics (MRSN) | 0.3 | $1.9M | 992k | 1.89 |
|
|
| Century Therapeutics (IPSC) | 0.2 | $1.1M | -50% | 667k | 1.71 |
|
| Aerovate Therapeutics (AVTE) | 0.2 | $973k | 465k | 2.09 |
|
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.1 | $715k | NEW | 312k | 2.29 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.1 | $639k | 176k | 3.63 |
|
|
| Neurogene (NGNE) | 0.1 | $629k | NEW | 15k | 41.96 |
|
| Rapt Therapeutics (RAPT) | 0.1 | $587k | 292k | 2.01 |
|
|
| Nkarta (NKTX) | 0.1 | $542k | -50% | 120k | 4.52 |
|
Past Filings by Octagon Capital Advisors
SEC 13F filings are viewable for Octagon Capital Advisors going back to 2020
- Octagon Capital Advisors 2024 Q3 filed Nov. 14, 2024
- Octagon Capital Advisors 2024 Q2 filed Aug. 14, 2024
- Octagon Capital Advisors 2024 Q1 filed May 15, 2024
- Octagon Capital Advisors 2023 Q4 filed Feb. 14, 2024
- Octagon Capital Advisors 2023 Q3 filed Nov. 14, 2023
- Octagon Capital Advisors 2023 Q2 filed Aug. 14, 2023
- Octagon Capital Advisors 2023 Q1 filed May 15, 2023
- Octagon Capital Advisors 2022 Q4 filed Feb. 14, 2023
- Octagon Capital Advisors 2022 Q3 filed Nov. 14, 2022
- Octagon Capital Advisors 2022 Q2 filed Aug. 15, 2022
- Octagon Capital Advisors 2022 Q1 filed May 16, 2022
- Octagon Capital Advisors 2021 Q4 filed Feb. 14, 2022
- Octagon Capital Advisors 2021 Q3 filed Nov. 15, 2021
- Octagon Capital Advisors 2021 Q2 filed Aug. 16, 2021
- Octagon Capital Advisors 2021 Q1 filed May 17, 2021
- Octagon Capital Advisors 2020 Q4 filed Feb. 16, 2021